



Yes  
You  
Health

## Product list

December 2025

**Farmaprojects**  
*polpharma*  
GROUP

# Under development generics

INN	PHARMACEUTICAL FORM	STRENGTH	REFERENCE PRODUCT
Alimentary tract & metabolism			
Empagliflozin*/Metformin	Film - coated tablets	5mg/500mg, 5mg/850mg, 5mg/1000mg, 12.5mg/500mg, 12.5mg/850mg, 12.5mg/1000mg	Synjardy® (Boehringer Ingelheim)
Allergy/Immuno			
Baricitinib*	Film - coated tablets	2mg, 4mg	Olumiaant® (Lilly)
Upadacitinib	Prolonged - release tablets	15mg, 30mg, 45mg	Rinvoq® (Abbvie)
Respiratory System			
Fluticasone/Vilanterol*	Inhalation powder	92mcg/22mcg, 184mcg/22mcg	Bro Ellipta® (GSK)
Umeclidinium/Vilanterol*	Inhalation powder	55mcg/22 mcg	Anoro Ellipta® (GSK)
Fluticasone/Umeclidinium/Vilanterol	Inhalation powder	100mcg/74.2mcg/62.5mcg, 200mcg/74.2mcg/62.5mcg	Trelegy Ellipta® (GSK)
Cardiology			
Finerenone*	Film - Coated Tablets	10mg, 20mg	Kerendia® (Bayer)
Bempedoic Acid	Film - Coated Tablets	180mg	Nilemdo® (Esperion, Daiichi Sankyo )
Bempedoic Acid / Ezitimibe	Film - Coated Tablets	180mg/10mg	Nustendi® (Esperion, Daiichi Sankyo )
Ramipril	Tablets	2.5mg, 5mg, 10mg	Delix® (Sanofi)
Valsartan	Film - coated tablets	40mg, 80mg, 160mg, 320mg	Diovan® (Novartis)
Valsartan/Hydrochlorothiazide	Film - coated tablets	80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, 320mg/25 mg	Codiovan® (Novartis)
Anti-infectives for systemic use			
Avibactam/Ceftazidime	Powder for Injection	500mg/2g	Zavicefta® (Pfizer)
Short RNA (Oligonucleotide)			

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Nusinersen	Solution for injection	12 mg/5ml vial (2.4mg/ml)	Spinraza® (Biogen)
Inclisiran	Solution for injection	284 mg/1.5 mL prefilled syringe (189 mg/mL)	Leqvio® (Novartis)

Central Nervous System

Cenobamate	Film – coated tablets	12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg	Ontozry® (SK Biopharmaceuticals)
------------	-----------------------	---	----------------------------------

Available

INN	PHARMA CEUTICA L FORM	STRENGTH	REFERENCE PRODUCT	LACTOSE FREE	STABILITY	SHELF LIFE
-----	-----------------------------	----------	----------------------	-----------------	-----------	------------

Alimentary tract & metabolism

Dapagliflozin* / Metformin	Film – coated tablets	5mg/850mg, 5mg/1000mg	Xigduo® (AstraZeneca)	Yes	II: available IVa: ext. from b IVb: available	36 months 36 months
Dapagliflozin*	Film – coated tablets	5mg, 10mg	Forxiga® (AstraZeneca)	Yes	II: available IVa: ext. from b IVb: available	36 months 36 months
Empagliflozin*	Film – coated tablets	10mg, 25mg	Jardiance® (Boehringer Ingelheim)	Yes	II: available IVa: ext. from b IVb: available	36 months 36 months – Not store above 30 oC
Linagliptin*	Film – coated tablets	5mg	Trajenta® (Boehringer Ingelheim)	Yes	II: available IVa: ext. from b IVb: available	36 months 36 months
Orlistat	Hard capsules	120mg	Xenical® (Roche)	Yes	II: available IVb: not available	24 months
Orlistat OTC	Hard capsules	60mg	Alli® (GSK)	Yes	II: available IVa: not available IVb: not available	24 months
Sitagliptin*	Film – coated tablets	25mg, 50mg, 100mg	Januvia® (Merck)	Yes	II: available IVa: not available IVb: available	36 months

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Sitagliptin*/ Metformin	Film – coated tablets	50mg/850mg, 50mg/1000mg	Janumet® (Merck)	Yes	II: available IVa: not available IVb: available	24 months
----------------------------	-----------------------------	----------------------------	---------------------	-----	--	-----------

### Anti-infectives for systemic use

Aciclovir	Tablets	200mg, 400mg, 800mg	Zovirax® (GSK)	Yes	II: available IVa: not available IVb: not available	36 months
-----------	---------	------------------------	----------------	-----	--	-----------

### Antineoplastic & Immunomodulating Agents

Apremilast*	Film – coated tablets	10mg, 20mg, 30mg	Otezla® (Celgene)	Yes	II: available IVa: not available IVb: not available	18 months (target 36)
-------------	-----------------------------	---------------------	----------------------	-----	--	-----------------------

### Blood & Blood forming organs

Apixaban*	Film – coated tablets	2.5mg, 5mg	Eliquis® (Bristol- Myers Squibb)	No	II: available IVa: ext. from b IVb: available	36 months
Rivaroxaban*	Film – coated tablets	2.5mg, 10mg, 15mg, 20mg	Xarelto® (Bayer)	No	II: on-going IVa: ext. from b IVb: on- going	24 months
Rivaroxaban*	Capsules	10mg, 15mg, 20mg	Xarelto® (Bayer)	No	II: available	24 months
Ticagrelor*	Film – coated tablets	60mg, 90mg	Brilique® (AstraZeneca)	Yes	II: available IVa: ext. from b IVb: available	36 months

### Cardiovascular System

Ramipril / Indapamide	Hard capsules (IR dosage form)	5mg/2.5mg, 10mg/2.5mg, 5mg/1.25mg, 10mg/1.25mg	New combination	No	II: available	36 months
Hydrochlorothi azide*	Tablets	12.5mg, 25mg, 50mg	Esidrex® (Novartis)	No	II: available IVa: not available IVb: not available	60 months
Ramipril / Amlodipine	Hard capsules	5mg/5mg, 5mg/10mg, 10mg/5mg, 10mg/10mg	Tritace® /Ramipril (Sanofi) & Norvasc®/Amlod ipine (Pfizer)	Yes	II: available IVa: not available IVb: not available	36 months

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Rosuvastatin	Film – coated tablets	5mg, 10mg, 20mg	Crestor® (AstraZeneca)	No	II: available IVa: (12 months) IVb: not available	36 months
Telmisartan / Amlodipine	Bilayered Tablets	40mg / 5mg, 40mg / 10mg, 80mg / 5mg, 80mg / 10mg	Twynsta® (Boehringer Ingelheim)	Yes	II: available IVa: ext. from b IVb: available	36 months
Dermatologicals						
Dimetindene	Gel	1mg /g (20g), 1mg /g (30g), 1mg /g (50g)	Fenistil(TM) (Novartis)	Yes	II: available IVa: ext. from b IVb: available	36 months
Genito-Urinary System & Sex Hormones						
Tadalafil*	Film – coated tablets	2.5mg, 5mg, 10mg, 20mg	Cialis® (Eli Lilly)	No	II: available IVa: ext. from b IVb: available	48 months
Musculoskeletal System						
Paracetamol/ Ibuprofen	Film – coated tablets	500mg/200mg	Nurofen Ultima® (Reckitt Benckiser)	II: available IVa: on-going IVb: on-going	36 months	
Nervous System						
Dimethyl Fumarate	Gastro – resistant hard capsules	120mg, 240mg	Tecfidera® (Biogen Idec)	Yes	II: on-going IVa: ext. from b IVb: on-going	36 months / do not store above 30oC (zone II) 24 months / do not store above 30oC (zone IVb)
Memantine hydrochloride	Film – coated tablets	10mg, 20mg	Ebixa® (Lundbeck)	No	II: available IVa: available IVb: no ext. from a	36 months
Quetiapine	Film – coated tablets	25mg, 100mg, 150mg, 200mg, 300mg	Seroquel® (AstraZeneca)	No	II: available IVa: available IVb: available	36 months
Respiratory System						
Xylomethazolin e/ Dexpanthenol OTC	Nasal spray solution	1.0mg / 50mg / ml (10ml), 0.5mg / 50mg / ml (10 ml)	Nasic(TM) (Cassella-med)	Yes	II: available IVa: ext. from b IVb: available	24 months (0.5mg) 36 months (1.0mg)
Glycopyrronium	Inhalation powder	44mcg	Seebri Breezhaler® (Novartis)	No	II: available	24 monts

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.

Glycopyrronium / Indacaterol	Inhalation powder	43mcg/85mcg	Ultibro Breezhaler® (Novartis)	No	II: available IVb: on-going	24 months
Vitamins & Minerals						
Cholecalciferol (Vitamin D3)	Soft capsule	20.000 IU	N/A	Yes	II: available IVa: not available	36 months

\*Polpharma Group API

CA: Dossier suitable for Canadian market

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subjected to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement.

It is within the buyer's responsibility and liability to check the patent situation of the product in the import market(s).

Based on exemption under art.5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Ticagrelor, Dapagliflozin and Linagliptin, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulation are met.



FARMAPROJECTS SAU  
Carrer Provença 392, 6ª Planta  
08025 Barcelona (Spain)  
Phone +34 93 508 05 00  
email: sales@farmaprojects.com

[www.farmaprojects.com](http://www.farmaprojects.com)

